Who Should Attend
This educational activity is intended for medical oncologists, radiation oncologists, thoracic surgeons, pulmonologists and other physicians in active clinical practice interested and/or involved in the management of patients with lung cancer.
Objectives
After successful completion of this continuing medical education activity, participants should be able to:
- Describe the epidemiology of lung cancer in Asia and evaluate emerging screening techniques
- Compare and contrast invasive versus non-invasive (MRI, CT, PET) procedures in the staging of lung cancer
- Discuss surgical issues and controversies related to the management and treatment of thoracic malignancies
- Examine the role of radiotherapy and emerging radiotherapeutic techniques in lung cancer
- Outline treatment options for patients with small cell lung cancer (SCLC), focusing on recent clinical advances in the management of this disease
- Translate the results of recent clinical trials in lung cancer and incorporate them into clinical practice
- Describe the emerging role of targeted therapies, specifically epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF) inhibitors, in the treatment of thoracic malignancies
- Evaluate the use of biomarkers to predict the efficacy of EGFR-inhibitors, antiangiogenic therapies and antineoplastic agents in the treatment of patients with lung cancer
- Analyze the current lung cancer research techniques and methodology utilized throughout Asia
Michael Boyer, MBBS, PhD, FRACP
Sydney Cancer Center
Camperdown, NSW Australia
Gilberto de Lima Lopes, Jr, MD
Johns Hopkins Singapore
International Medical Centre
Singapore, Singapore
Juntima Euathrongchit, MD
Chiang Mai University
Chiang Mai, Thailand
Stefano Gasparini, MD, FCCP
Azienda Ospedali Riuniti
Ancona, Italy
Norihiko Ikeda, MD, PhD
Tokyo Medical University
Tokyo, Japan
Guo-Liang Jiang, MD, FACR
Fudan University Cancer Hospital
Shanghai, China
Nirush Lertprasertsuk, MD, PhD
Chiang Mai University
Chiang Mai, Thailand
Tetsuya Mitsudomi, MD
Aichi Cancer Center Hospital
Nagoya, Japan
Tony Mok, MD
Chinese University of Hong Kong
Hong Kong, China
Robert Pirker, MD
Medical University of Vienna
Vienna, Austria
Pieter E. Postmus, MD, PhD
Free University Medical Center
Amsterdam, the Netherlands
Suresh S. Ramalingam, MD
Emory University School of Medicine
Atlanta, Georgia, United States
Somchareon Saeteng, MD
Chiang Mai University
Chiang Mai, Thailand
Giorgio V. Scagliotti, MD, PhD
University of Turin
Orbassano, Italy
Lu Shun, MD
Shanghai Chest Hospital
Shanghai. China
Virote Sriuranpong, MD, PhD
Chulalongkorn University
The King Chulalongkorn Memorial Hospital
Bangkok, Thailand
Qian Tao, PhD
Chinese University of Hong Kong
Hong Kong, China
Sumitra Thongprasert, MD
Maharaj Nakorn Chiang Mai Hospital
Chiang Mai, Thailand
Robert J. van Klaveren, MD, PhD
University Hospital Rotterdam
Rotterdam, The Netherlands
Yi-Long Wu, MD
Guangdong General Hospital
Guangzhou, China
Benny C. Y. Zee, PhD
Chinese University of Hong Kong
Centre for Clinical Trials
Sha Tin, NT
Hong Kong, China
Friday, 11 September 2009
8:00
Welcome
Tony Mok, MD
Sumitra Thongprasert, MD
Session I: Introductory lectures
8:15
Lung cancer in Asia
Tony Mok, MD
9:00
Pathological results of lung cancer in Chiang Mai
Nirush Lertprasertsuk, MD, PhD
9:20
Lung cancer screening with spiral CT scan: Where are we?
Robert J. van Klaveren, MD, PhD
9:40
Coffee break
Session II: Surgery and staging
10:10
The new staging system for lung cancer
Pieter E. Postmus, MD, PhD
10:30
Utilization of CT scan, MRI and PET-CT for staging and monitoring of lung cancer
Juntima Eauthrongchit, MD
10:50 Minimally invasive techniques for staging the mediastinum
Stefano Gasparini, MD, FCCP
11:10
Endoscopic ultrasonography for peripheral lung lesion
Norihiko Ikeda, MD, PhD
11:30
Lunch break
Session III: Early stage disease
12:30
Neo-adjuvant and adjuvant therapy for early stage NSCLC
Giorgio V. Scagliotti, MD, PhD
12.50
The rationale and prospect of molecular targeted therapy in adjuvant therapy
Suresh S. Ramalingam, MD
13:10
Radiation therapy and stereotatic RT for early stage NSCLC
Guo-Liang Jiang, MD, FACR
13:30
VATS for primary resection and metastatectomy
Somchareon S. Saeteng, MD
14:00
Coffee break
Keynote lecture
14:30
Maintenance therapy: Yes or no
Suresh Ramalingam, MD
Session IV: Interactive case presentations
15:15
Case 1: Surgically-based case discussion
Somchareon Saeteng, MD
Case 2: Systemic treatment of advanced non-small cell lung cancer in Asia: Current evidence and practice
Gilberto de Lima Lopes, Jr., MD
Case 3: Tyrosine kinase inhibitor in non-small cell lung cancer
Virote Sriurangpong, MD
16:15
Adjourn
Saturday, 12 September 2009
8:00
Welcome
Giorgio V. Scagliotti, MD, PhD
Sumitra Thongprasert, MD
8:15
Keynote lecture: Monoclonal antibodies in NSCLC
Robert Pirker, MD
Session V: Translational research
9:00
Novel therapeutic targets in lung cancer
Tetsuya Mitsudomi, MD
9:20
Personalized medicine via molecular diagnostics
Giorgio V. Scagliotti, MD, PhD
9:40
EGFR mutations: Laboratory perspective versus clinical perspective
Laboratory Angle: Speaker invited
Clinical Angle: Tony Mok, MD
10:10
An introduction to cancer epigenetics
Qian Tao, PhD
10:30
Coffee break
Session VI: Emerging data and clinical trial updates
11:00
EGFR inhibitors, angiogenesis inhibitors and tyrosine kinase inhibitors
Lu Shun, MD
11:30
Emerging new therapies in NSCLC: HDAC inhibitors, Hedgehog inhibitors, vaccines, TRAIL antibodies
Michael Boyer, MBBS, PhD, FRACP
12:00
Best of ASCO and IASLC 2009: Local-regional disease
Sumitra Thongprasert, MD
12:30
Best of ASCO and IASLC 2009: Metastatic disease
Tony Mok, MD
13:00
Lunch break
Session VII: Special topics in thoracic oncology
14:00
Novel agents and targets in anti-angiogenesis and anti-vascularization
Giorgio V. Scagliotti, MD, PhD
14:30
Small cell lung cancer
Pieter E. Postmus, MD, PhD
15:00
Areas of therapeutic neglect
Yi- Long Wu,MD
15:30
Coffee break
Session VIII: Lung cancer research methodology
15:50
Statistics for clinicians
Benny C. Y. Zee, PhD
16:10
Lung cancer study groups and research plan in the United States
Suresh S. Ramalingam, MD
16:30
Quality of life in lung cancer
Sumitra Thongprasert, MD
16:50
Adjourn
Participants interested in presenting data should submit abstracts online at www.imedex.com by 6 August 2009. Abstracts are subject to acceptance by the Scientific Committee. Once accepted, abstracts will be published in the final course book and scheduled for poster presentation.
Acceptance notifications and guidelines for poster presentation will be sent on 17 August 2009. Authors of accepted abstracts who have not registered will have until 28 August 2009 to do so at the rate of $249. After this date, abstracts without registered presenters will be disregarded.
Submit your abstract online by going to www.imedex.com, selecting this Congress and following the instructions in the “Abstracts” section.
Abstract Guidelines
- Follow the online instructions
- Abstracts must be written in English
- Accepted format: Word document format, 9 point Arial font, 500 word count limit
- Use a concise title
- List affiliations of author(s) as briefly as possible, with city, state and country
- Place an asterisk (*) before the name of the presenting author
- Use standard and well-accepted abbreviations
- When using references, use standard and well-accepted formats
- Abstract content should be single-spaced, typed in lower case and contain:
- Purpose of the study
- Summarized description of the project
- Results and conclusions
Submission Deadline
6 August 2009
Registration Fees
Discounted . . . . . . . . . . . . . . . . . . . . . . . . . . . . $249.00
If payment received by 3 September 2009
Full/Onsite . . . . . . . . . . . . . . . . . . . . . . . . . . . . $349.00
If payment received by 3 September 2009
Group discount (physicians only)*. . . . . . . . . . . -$50.00
*cannot be combined with any other discounts
Nurses/Residents/Students*. . . . . . . . . . . . . . . .$99.00
*proof of eligibility must accompany registration
*cannot be combined with any other discounts
To Register: You may register online by 3 September 2009 at www.imedex.com, by calling Imedex at +1 (678) 242 0906 or by returning the registration form in this program by mail or fax. If you mail the form, please keep a copy for your records. Registration confirmations will be issued before the meeting. To qualify for special registration fees, registration and full payment must be received by Imedex by the dates specified.
Group Discounts: Each one of multiple registrants from the same institute or practice each receive a $50 discount off the published registration fees, provided all registration forms and payments are received together. Only one discount will apply per physician. Discounts are not available for nurses, residents and students. Payment: To pre-register, registration and payment must be received no later than 3 September 2009. Please register onsite after this date. Contact Imedex at +1 (678) 242 0906 or visit our website at www. imedex.com to ensure the course is being held as scheduled and to confirm that the meeting is not full. Registration fees must be remitted by credit card or check. Checks should be payable to Imedex. Attendee is not registered until full payment is received.
Registration Fee Inclusions: Registration fees include admittance to all scientific sessions, conference materials, and all event functions as specified in the program.
Cancellation: For registration fees to be refunded, written notice of cancellation must be received at meetings@imedex.com no later than 3 September 2009. The amount of registration fees remitted, less a $75 administrative charge, will be refunded after the conference. Substitutions are accepted with written notification. No refunds will be made if notice is received after 3 September 2009.
Imedex does not accept responsibility for covering travel, accommodation or any other costs incurred by registrants in the rare event that this program should be canceled for any reason. Every effort will be made to give reasonable notice in the event of cancellation. The event agenda is subject to change without notice.
Sheraton Grande Sukhumvit
250 Sukhumvit Road
Bangkok 10110
Thailand
Tel.: +1 (66) 02 6498888
Fax: +1 (66) 02 6498000
http://www.sheratongrandesukhumvit.com
The Sheraton Grande Sukhumvit is a distinguished hotel in the heart of Asia’s most intriguing city. The towering landmark rises majestically above an inspiring cityscape.
A place of elegance and charm, it provides an enriching guest experience and the opportunity begin a personal journey of discovery in Bangkok.
Defined by grand designs and opulent interiors, the Sheraton Grande Sukhumvit offers its guests a refined and gratifying lifestyle. Exquisite living spaces and tasteful décor, award-winning restaurants, an intimate spa, exceptional business and function facilities, and unrivalled technology all combine to deliver an unforgettable personal experience.
For the convenience of attendees, a limited number of rooms have been reserved until 25 August 2009 at a discounted rate of BAHT 5,800 deluxe single or BAHT 6,300 deluxe double occupancy, plus service charge, currently at 10% and 7% VAT. This rate is not guaranteed outside the conference dates or after 25 August 2009.
To reserve your room please contact the Sheraton Grande Sukhumvit reservations department at +1 (66) 02 6498888. To receive the group rate, callers must identify themselves as being with the 3rd Asian Pacific Conference: Perspectives in Lung Cancer group.
Reservations can also be Reservations can also be made on line at http://www.starwoodmeeting.com/StarGroupsWeb/res?id=0905298456&key=8BE2A. Reservation requests received after 25 August 2009 may not be guaranteed the group rate.
Dear Colleague,
It is our pleasure to invite you to the Third Asian Pacific
Conference: Perspectives in Lung Cancer which will be held
11-12 September 2009 in Bangkok, Thailand. Attendees from
all lung cancer-related disciplines will find it to be a stimulating
interactive and educational experience!
Created to provide state-of-the-art diagnosis and treatment
information, this comprehensive Conference focuses on the
multimodal management of lung cancer. Guided by expert
faculty from Asia, Europe, and North America, this conference
features interactive case presentations that focus on innovations
in diagnosis and staging, the latest therapies and techniques in
the multidisciplinary management of non-small cell lung cancer,
mesothelioma and small cell lung cancer.
As lung cancer research and treatment are constantly evolving,
there are many issues in disease biology, management, and
research that are intensely debated among those involved in these
fields. Attendees will not only update their knowledge, but confirm
their current practices, focus on the trends and evolutions worth
watching and receive valuable take-home information on exciting
new treatments and approaches.
We look forward to welcoming you in Bangkok, one of the most
cosmopolitan, contrasting and compelling cities in Asia. We know
you will find the Third Asian Pacific Conference: Perspectives
in Lung Cancer to be a world-class educational event.
Sincerely,
Tony Mok, MD
Giorgio V. Scagliotti, MD, PhD
Chairs
Sumitra Thongprasert, MD
Local Chair
ORGANIZER
Imedex
4325 Alexander Drive
Alpharetta, GA 30022-3740 USA
Tel.: +1 (770) 751 7332
Fax: +1 (770) 751 7334
Email: meetings@imedex.com
Web: www.imedex.com
Imedex is a brand and assumed name used by Imedex, LLC (hereby referred to as Imedex). Imedex is solely responsible for this agenda’s content. Although Imedex attempts to ensure that the information in our program is accurate and timely, matters and opinions discussed and/or presented with respect to clinical matters are those of the discussion participants only, and not necessarily those of Imedex. Moreover, although Imedex attempts to identify and integrate the most qualified medical professionals in our program, TO THE FULLEST EXTENT PERMITTED BY LAW, IMEDEX EXPRESSLY DISCLAIM ALL WARRANTIES, EITHER EXPRESS OR IMPLIED, STATUTORY OR OTHERWISE, INCLUDING BUT NOT LIMITED TO THE IMPLIED WARRANTIES OF MERCHANTABILITY, NON-INFRINGEMENT OF THIRD PARTIES’ RIGHTS, AND FITNESS FOR A PARTICULAR PURPOSE, WITH RESPECT TO THE CONTENT PRESENTED. IMEDEX FURTHER MAKES NO REPRESENTATIONS OR WARRANTIES ABOUT THE ACCURACY, RELIABILITY, COMPLETENESS OR TIMELINESS OF THE CONTENT OR ANY MATERIAL PRESENTED.
In addition, the material presented and related discussions are not intended to be medical advice, and the presentation or discussion of such material is not intended to create and does not establish a physician-patient relationship. Medical advice of any nature should be sought from an individual’s own physician.
Neither Imedex nor any of its subsidiaries or affiliates is affiliated with or formally endorsed by a medical society.
©2008 Imedex®, LLC. All rights reserved.
Reproduction in whole or part is prohibited without prior written consent from Imedex and contributing faculty.
The following companies have provided an educational grant in support of this conference:
BRONZE
Millennium
Pharmaceuticals, Inc.
CORPORATE
Several options are available to companies interested in supporting this Congress. For more information, please contact Imedex at +1(770) 751 7332, or by email at cme@imedex.com.
Opportunities are available to companies interested in exhibiting at this conference. For more information, please contact Cori Gunter at +1(678) 242 0712, or by email at c.gunter@imedex.com.
